Evanson Asset Management LLC grew its stake in shares of Pfizer Inc. (NYSE:PFE) by 22.6% during the 3rd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 21,924 shares of the biopharmaceutical company’s stock after purchasing an additional 4,047 shares during the period. Evanson Asset Management LLC’s holdings in Pfizer were worth $788,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors also recently modified their holdings of PFE. Greylin Investment Mangement Inc. boosted its position in shares of Pfizer by 1.3% in the 3rd quarter. Greylin Investment Mangement Inc. now owns 47,685 shares of the biopharmaceutical company’s stock worth $1,713,000 after buying an additional 600 shares in the last quarter. Murphy Capital Management Inc. boosted its position in shares of Pfizer by 2.8% in the 3rd quarter. Murphy Capital Management Inc. now owns 57,612 shares of the biopharmaceutical company’s stock worth $2,070,000 after buying an additional 1,589 shares in the last quarter. Domani Wealth LLC boosted its position in shares of Pfizer by 5.9% in the 3rd quarter. Domani Wealth LLC now owns 5,579 shares of the biopharmaceutical company’s stock worth $200,000 after buying an additional 310 shares in the last quarter. Carlton Hofferkamp & Jenks Wealth Management LLC boosted its position in shares of Pfizer by 1.4% in the 3rd quarter. Carlton Hofferkamp & Jenks Wealth Management LLC now owns 61,425 shares of the biopharmaceutical company’s stock worth $2,198,000 after buying an additional 856 shares in the last quarter. Finally, Larson Financial Group LLC boosted its position in shares of Pfizer by 28.1% in the 3rd quarter. Larson Financial Group LLC now owns 6,675 shares of the biopharmaceutical company’s stock worth $240,000 after buying an additional 1,463 shares in the last quarter. Institutional investors own 71.69% of the company’s stock.
In related news, major shareholder Pfizer Inc acquired 50,000 shares of the company’s stock in a transaction dated Tuesday, September 17th. The stock was bought at an average price of $18.00 per share, with a total value of $900,000.00. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Scott Gottlieb acquired 3,000 shares of the company’s stock in a transaction dated Friday, August 23rd. The shares were bought at an average cost of $34.72 per share, with a total value of $104,160.00. Following the purchase, the director now owns 3,000 shares in the company, valued at $104,160. The disclosure for this purchase can be found here. Corporate insiders own 0.09% of the company’s stock.
PFE stock traded up $0.52 during trading on Friday, hitting $36.31. The stock had a trading volume of 10,877,390 shares, compared to its average volume of 19,407,336. The company’s 50 day moving average price is $35.94 and its two-hundred day moving average price is $39.97. Pfizer Inc. has a 1-year low of $33.97 and a 1-year high of $46.47. The stock has a market cap of $195.97 billion, a price-to-earnings ratio of 12.10, a price-to-earnings-growth ratio of 2.82 and a beta of 0.66. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.21 and a current ratio of 1.47.
Pfizer (NYSE:PFE) last posted its quarterly earnings data on Monday, July 29th. The biopharmaceutical company reported $0.80 EPS for the quarter, beating the Zacks’ consensus estimate of $0.75 by $0.05. Pfizer had a net margin of 23.58% and a return on equity of 28.10%. The company had revenue of $13.26 billion during the quarter, compared to the consensus estimate of $13.43 billion. During the same quarter in the prior year, the company posted $0.77 EPS. The company’s quarterly revenue was down 1.5% compared to the same quarter last year. As a group, sell-side analysts forecast that Pfizer Inc. will post 2.81 earnings per share for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 2nd. Stockholders of record on Friday, November 8th will be paid a dividend of $0.36 per share. This represents a $1.44 dividend on an annualized basis and a dividend yield of 3.97%. The ex-dividend date is Thursday, November 7th. Pfizer’s dividend payout ratio is currently 48.00%.
PFE has been the topic of several recent research reports. Bank of America lowered shares of Pfizer from a “buy” rating to a “neutral” rating in a research report on Tuesday, July 30th. JPMorgan Chase & Co. boosted their target price on shares of Pfizer from $37.00 to $46.00 and gave the company a “neutral” rating in a research note on Thursday, September 19th. They noted that the move was a valuation call. Zacks Investment Research raised shares of Pfizer from a “sell” rating to a “strong-buy” rating and set a $38.00 target price for the company in a research note on Tuesday, October 1st. DZ Bank raised shares of Pfizer from a “sell” rating to a “hold” rating and set a $36.00 target price for the company in a research note on Wednesday, August 28th. Finally, UBS Group reissued a “neutral” rating and issued a $43.00 target price on shares of Pfizer in a research note on Monday, August 5th. Twelve research analysts have rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the company. Pfizer has an average rating of “Hold” and an average price target of $45.20.
Pfizer Company Profile
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.
Featured Article: What is an economic bubble?
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.